Clinical Trial Update: PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations [Phase 1]

View source ↗

Summary

Phase 1 trial results evaluate BAY86-9596 as a PET tracer for diagnostic imaging across cancer and inflammatory conditions. The study reports PET/CT dosimetry, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Head and Neck Cancer
• Inflammation
• Non-small Cell Lung Cancer

Drugs mentioned

• BAY86-9596

Snippet

Sponsor: Life Molecular Imaging SA | Conditions: Diagnostic Imaging | Phase 1 | Status: COMPLETED